health_en

ACG joins coveted list of WEF’s Global Lighthouse Network

–  Capsule facility in Pithampur, Madhya Pradesh demonstrates excellence in technology enabled operations that transform value chains ACG, the world’s largest integrated supplier and service provider to pharmaceutical industry celebrated the inclusion of its capsule manufacturing facility in Pithampur, India, into the esteemed Global Lighthouse Network (GLN) by the World Economic Forum. WEF’s Global Lighthouse […]

thaipr.net

19 ธ.ค. 66

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

10+ Emerging Markets, Japan & ANZ Transition in Final Phase Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. […]

thaipr.net

19 ธ.ค. 66

BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDx™ IN JAPAN

BioCheetah Pte. Ltd. (Head Office: Singapore; CEO: Dr. Lee Kian Chung; hereinafter “BioCheetah”) and Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter “Nippon Kayaku”) announce that the two companies have entered into an exclusive licensing and commercialization agreement to develop and market a novel urinary biomarkers-based bladder cancer diagnostic assay kit, […]

thaipr.net

15 ธ.ค. 66

Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments. Both the…

thaipr.net

13 ธ.ค. 66

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, today presented results from a new post hoc analysis of the pivotal EMERALD clinical study that demonstrated a clinically meaningful improvement in…

thaipr.net

12 ธ.ค. 66

Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner

Merck, a leading science and technology company, and the Acceleration Consortium, based at the University of Toronto, Canada, today jointly announced that their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on GitHub, with an unrestricted Apache 2.0 license. The joint open-source initiative combines the Merck portfolio of use cases with the Acceleration Consortium’s world-leading […]

thaipr.net

7 ธ.ค. 66
1 … 18 19 20 21 22 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.